Cooley Advises Revance on its Initial Public Offering

Palo Alto, Calif. – February 13, 2014 – Cooley LLP announced today that it advised Revance Therapeutics, Inc. on its $110 million IPO. Revance is a specialty biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic indications. It now trades on the NASDAQ Global Stock Market under the symbol "RVNC."

The Cooley corporate and securities team advising Revance included partners Mark Weeks, chair of Cooley's medical device practice, and Gordon Ho, as well as special counsel Marina Remennik, and associates Rose Standifer, Patty Cheng, Josh Seidenfeld and Sale Kwon. Critical support for the offering was provided by partners Natasha Leskovsek (regulatory), Mark Windfeld-Hansen (tax) and Renee Deming (compensation and benefits).

This offering follows Cooley's record year for capital markets work in 2013 in which the firm advised on 60 public offerings, including 23 IPOs, raising more than $8.4 billion. Year-to-date, Cooley has advised on 20 public offerings, including 10 IPOs.

About Cooley LLP

Cooley's attorneys solve legal issues for entrepreneurs, investors, financial institutions and established companies. Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and bet-the-company litigation, often where innovation meets the law.

Cooley has more than 750 lawyers across 11 offices in the United States and China.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.